Infection
Vrelysin by Intralytix for Vancomycin-Resistant Enterococcus faecium Infections: Likelihood of Approval
Nov
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vrelysin overview
Vrelysin is under development for the treatment of vancomycin resistant Enterococcus (VRE) infections. The therapeutic candidate comprises of a cocktail of lytic Enterococcus-specific bacteriophages, administered orally.
Intralytix overview
Intralytix is a biotechnology company that develops, produces and markets bacteriophage based products to control bacterial pathogens. It offers food safety products, pet food safety products and pre-harvest interventions. Its food safety products include listshield, ecoshield, salmofresh and shigashield. Intralytix food safety products help prevent Listeria monocytogenes and Escherichia coli contamination in food and food processing facilities. Its animal health products are effective against Clostridium perfringens contamination in live poultry. The company also commercializes its bacteriophage technology for use in food production and processing, environmental cleanliness, veterinary applications and human therapy. Intralytix is headquartered in Baltimore, Maryland, the US.
For a complete picture of Vrelysin’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
